Medical
About Us
Our Fields
In 2020, there were approximately 241 million estimated cases of malaria identified globally [*1]. However, approximately 20–70% of the malaria infections are reported to be undetected by current non-nucleic acid tests such as microscopy and rapid diagnostic tests (RDTs) [*2].
Microscopy and RDTs can detect Plasmodium infection when the parasite count is higher than 50,000–200,000/mL of whole blood [*2].
Malaria LAMP is a comprehensive molecular solution introduced for the diagnosis of malaria. The limit of detection is 1–2 parasites/µL [*3], which is far lower than microscopy and RDTs. In addition, Malaria LAMP can differentiate between Plasmodium pan species, P. falciparum and P. vivax, and has a sensitivity of 84–94%, a specificity of >92% [*4].
The assay has potential as a reference standard in resource limited settings; and as a tool for surveillance and screening when a highly sensitive assay is needed.
Malaria LAMP offers a field-friendly alternative to PCR tests as it can be set easily outside reference laboratories. Moreover, Malaria LAMP presents many operational advantages over PCR, including minimal equipment using heat-blocks, shorter time-to-result (40 min), lower cost and visible results to the naked eye under blue LED light.
HUMAN Gesellschaft für Biochemica und Diagnostica mbH sells products above. (except Japan, China, Korea, Taiwan and Thailand). Please visit HUMAN GmbH website.
If you have any question about using Malaria products, please refer to FAQ about Malaria LAMP. *This link will direct you to a website of HUMAN GmbH.